Back to discover
Disease

Multiple Sclerosis, Chronic Progressive

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHMultiple Sclerosis, Chronic Progressive
3
Publications
24
Clinical trials
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones16View all 16
Results posted 2
Results expected 5
Recently completed 3
Other updates 5
+8 more in the activity timeline below
Activity timeline16

Clinical trials

11 sponsors · 3 new · 4 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple Sclerosis

Phase 3 · Recruiting · Novartis Pharmaceuticals

A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)

Phase 3 · Active, not recruiting · Immunic AG

Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Phase 2/3 · Recruiting · TG Therapeutics, Inc.

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Phase 3 · Recruiting · University Hospital, Montpellier

A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)

Phase 3 · Active, not recruiting · Immunic AG

An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis

Phase 3 · Active, not recruiting · TG Therapeutics, Inc.
Recently completed

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)

Phase 3 · Completed · Sanofi

Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS

Phase 3 · Completed · Novartis Pharmaceuticals

Open-Label, Randomized, Multicenter, Multiple-Dose, Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension

Phase 3 · Completed · Biogen

AGNOS: An 18-month, Open-label, Multi-Center Phase IV Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes.

Phase 4 · Completed · Novartis Pharmaceuticals

A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Phase 3 · Completed · Hoffmann-La Roche

An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab

Phase 4 · Completed · Genentech, Inc.

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20092025
Major themes5
  • Brain1
  • Metformin1
  • Multiple Sclerosis1
  • Multiple Sclerosis, Chronic Progressive1
  • Nerve Degeneration1
Leading journals3
  • Brain : a journal of neurology1
  • Frontiers in immunology1
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics1
Leading researchers8
  • Albelo-Martínez M1
  • Bjerke M1
  • Bramow S1
  • Cambron M1
  • D' Haeseleer M1
  • D'hooghe MB1
  • Dal-Bianco A1
  • De Keersmaecker AV1
Affiliations (unnormalised)6
  • Antwerp University Hospital1
  • Biomedical Research Institute1
  • Brown University Health and Rhode Island Hospital1
  • Center for Brain Research1
  • Center for Neurosciences1
  • Center of Health Economic Research and Modelling Infectious Diseases1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)

Identifiers
MeSHMultiple Sclerosis, Chronic Progressive
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.